|
Press Releases
-
August 12, 2008
BioSyntech Announces First Quarter 2009
Financial Results
LAVAL, Quebec — August 12, 2008 — BioSyntech, Inc. (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced its financial and operational results for first quarter of its fiscal year 2009, ended June 30, 2008.
More
-
July 22, 2008
BioSyntech Appoints New Board Members
Laval, Québec, July 22, 2008 — BioSyntech, Inc. (the “Company”) (TSX:BSY) is pleased to announce that Mr. Michel Lagueux, Dr. Karen Hong, Mr. Eric W. Linsley and Mr. Winston Black have been appointed to the Board of Directors, effective immediately.
More
-
July 18, 2008
BioSyntech Announces Exercise of Over-Allotment Option
Laval, Québec, July 18, 2008 — BioSyntech, Inc. (the “Company”) (TSX:BSY) is pleased to announce that as part of the exercise of the over-allotment option in its previously announced bought deal,
More
-
July 15, 2008
BioSyntech Completes $11 Million Bought Deal
Laval, Québec, July 15, 2008 — BioSyntech, Inc. (the “Corporation”) (TSX:BSY) is pleased to announce that it has closed its previously announced bought deal.
More
-
July 08, 2008
BioSyntech, Inc. Announces Filing of Final Prospectus and Obtention of Conditional Listing Approval from the TSX and Provides an Update on Its Convertible Debenture Offering
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.
More
-
June 27, 2008
BioSyntech Announces 2008 Year-End
Financial Results and the Adoption of a New Strategic Plan
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.
More
-
June 20, 2008
BioSyntech Announces Increase to Bought Deal
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.
More
-
June 18, 2008
BioSyntech Responds To TSX Listing Review
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.
More
-
June 16, 2008
BioSyntech Announces $10 Million Bought Deal Financing
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.
More
-
April 24, 2008
BioSyntech Announces BST-DermOnTM Abstract Selected For Poster Presentation at the 2008 World Union of Wound Healing Societies Congress
LAVAL, Quebec, April 24, 2008 — BioSyntech, Inc. (“BioSyntech” or “the Company”) (TSX: BSY), a biotechnology company developing novel products in regenerative medicine, today announced that its abstract summarizing the safety and effectiveness of BST-DermOn™ in promoting the healing of various types of chronic wounds that have failed previous treatments,
More
-
April 07, 2008
BioSyntech Receives ISO13485:2003 Certification For Its Quality Management System
LAVAL, Quebec, April 07, 2008 — BioSyntech, Inc. (“BioSyntech” or “the Company”) (TSX: BSY), a biotechnology company developing novel products in regenerative medicine, today announced that it has achieved international certification under the stringent and globally recognized ISO 13485:2003
More
-
March 17, 2008
BioSyntech Announces Positive Preliminary Interim Data
for BST-CarGel® Clinical Trial
LAVAL, Quebec, March 17, 2008 — BioSyntech, Inc. (“BioSyntech” or “the Company”) (TSX: BSY), a biotechnology company developing novel products in regenerative medicine, today announced it has received positive preliminary results from a prospectively planned six-month interim analysis of its Canadian-European pivotal clinical trial for BST-CarGel®.
More
-
March 04, 2008
BioSyntech Announces Five Poster Presentations at 54th Annual Meeting of the Orthopaedic Research Society
LAVAL, Quebec — March 4, 2008 — BioSyntech, Inc. (“BioSyntech” or “the Company”) (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced that five abstracts have been selected for presentation as posters at the 54th Annual Meeting of the Orthopaedic Research Society (“ORS”) held from March 2-5, 2008 in San Francisco, California.
More
-
February 14, 2008
BioSyntech announces third quarter 2008 financial results
LAVAL, Quebec — February 13, 2008 — BioSyntech, Inc. (“BioSyntech” or “the Company”) (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced its financial results for the three and nine-month periods ended December 31, 2007.
More

Archives
-
November 27, 2007
BioSyntech Awarded 2007 Innovation Award from ADRIQ
LAVAL, Quebec — November 27, 2007 — BioSyntech, Inc. (“BioSyntech” or the “Company”) (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced it has been awarded the 2007 Innovation Award in the “Partnership” category by the Association de la Recherche Industrielle du Quebec (ADRIQ) for its successful partnership with the École Polytechnique de Montréal (École Polytechnique).
More
-
November 12, 2007
Biosyntech Announces Second Quarter 2008 Financial Results
LAVAL, Quebec — November 12, 2007 — BioSyntech, Inc. (“BioSyntech” or “the Company”) (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced its financial results for the three and six-month periods ended September 30, 2007.
More
-
August 13, 2007
BioSyntech announces first quarter 2008
financial results
LAVAL, Quebec, Canada — August 13, 2007 — BioSyntech, Inc. (“BioSyntech” or “the Company”) (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced financial results for the first quarter ended June 30, 2007.
More
-
July 11, 2007
Biosyntech appoints new vice president, regulatory affairs and quality
LAVAL, Quebec, Canada — July 11, 2007 —- BioSyntech, Inc. ("BioSyntech" or "the Company") (TSX: BSY) today announced that Mrs. Flor del Pilar Arana has been appointed Vice President, Regulatory Affairs and Quality.
More
-
June 29, 2007
BioSyntech announces fourth quarter and 2007 year-end
financial results
LAVAL, Quebec, Canada — June 29, 2007 — BioSyntech, Inc. (“BioSyntech” or “the Company”) (TSX: BSY) today announced financial results for the fourth quarter and fiscal year ended March 31, 2007.
More
-
June 14, 2007
BioSyntech reaches significant BST-CarGel® clinical milestone
LAVAL, Quebec, Canada — June 14, 2007 — BioSyntech Inc. (TSX: BSY) announced today that it has completed the enrolment of a 20 patient subset of its ongoing Canadian-European BST-CarGel® pivotal trial. The data collected from these patients will be submitted to the U.S. Food and Drug Administration as a pilot study in support of an Investigational Device Exemption (IDE) for a US pivotal trial.
More
-
April 02, 2007
BioSyntech announces refinancing of loan
LAVAL, Québec, Canada —April 2, 2007 — BioSyntech, Inc. (“BioSyntech” or the “Company”) (TSX: BSY) today announced that it has entered into a formal agreement with the Business Development Bank of Canada (the “BDC”), to refinance part of their loan of $2,500,000 by way of conventional mortgage.
More
-
February 14, 2007
BioSyntech reports its third quarter results
LAVAL, Québec, Canada — February 14, 2007 — BioSyntech, Inc. (“BioSyntech” or “the Company”) (TSX: BSY) today reported its results for its third quarter and nine-month period ended December 31, 2006.
More
-
February 08, 2007
BioSyntech announces start of patient recruitment into
BST-DermOnTM pivotal clinical trial
LAVAL, Quebec, Canada — February 8, 2007 — BioSyntech Inc. (TSX: BSY) announced today the start of recruitment into its Canadian pivotal clinical trial for BST-DermOnTM, a medical device designed to repair chronic wounds and based on the natural polysaccharide chitosan. Dr. Gary Sibbald, an internationally recognized leader in the field of dermatology and wound repair, is the Principal Investigator for this trial.
More

-
December 04, 2006
Monday, December 4 - BioSyntech, Inc. Opens the Markets
Claude LeDuc, CEO of BioSyntech, Inc., opened the markets today. BioSyntech is a biotechnology company specializing in the discovery, development, and manufacturing of innovative, cost-effective, and physician-friendly therapeutic thermogels for regenerative medicine (tissue repair) and therapeutic delivery. BioSyntech trades on TSX under the stock symbol BSY.
More
-
November 29, 2006
BioSyntech reports second quarter results
LAVAL, Québec, Canada — November 29, 2006 — BioSyntech, Inc. ("BioSyntech" or "the Company") (TSX: BSY) today reported its results for the second quarter and six-month period ended September 30, 2006.
More
-
November 20, 2006
BioSyntech signs scientific collaboration agreement with Nicholas Piramal
Laval, Quebec, Canada — November 20, 2006 — BioSyntech, Inc. (“BioSyntech” or the “Company”) (TSX:BSY) is pleased to announce the signing of a scientific collaboration between the Company and their biopharmaceutical partner Nicholas Piramal.
More
-
October 30, 2006
BioSyntech shares begins trading on the TSX today
LAVAL, Québec, Canada — October 30, 2006 — BioSyntech, Inc. (“BioSyntech” or the “Company”) (TSX V: BSY) is pleased to announce that its common shares will commence trading on the Toronto Stock Exchange ("TSX") at the open of trading today, Monday October 30, 2006 under the symbol “BSY”.
More
-
October 11, 2006
BioSyntech Receives Notice of Allowance from
the US Patent and Trademark Office
on Key BST-CarGel® Patent
LAVAL, Québec, Canada — October 11, 2006 — BioSyntech, Inc. (“BioSyntech” or the “Company”) (TSX V: BSY) announced today that on September 20, 2006, it received a Notice of Allowance from the US Patent and Trademark Office on their key BST-CarGel® patent entitled, “Composition and method for the repair and regeneration of cartilage and other tissues”. BST CarGel®, the Company's lead product,
More
-
September 29, 2006
BioSyntech announces conditional approval for listing on the Toronto Stock Exchange
LAVAL, Québec, Canada — September 29, 2006 — BioSyntech, Inc. (“BioSyntech” or the “Company”) (TSX V: BSY) is pleased to announce that its application to graduate to the Toronto Stock Exchange has been approved, subject only to the filing of final documentation.
More
-
September 25, 2006
Annual meeting of stockholders of BioSyntech, Inc.
LAVAL, QUEBEC, September 25, 2006 – Mr. Joseph Benarrosh, Chairman of the Board announces the Annual Meeting of Stockholders of BioSyntech, Inc.
More
-
August 25, 2006
BioSyntech reports first quarter results
LAVAL, Québec, Canada — August 25, 2006 — BioSyntech, Inc. ("BioSyntech" or "the Company") (TSX-V: BSY) today reported its results for the first quarter ended June 30, 2006.
More
-
August 24, 2006
BioSyntech receives approval for Canadian BST-DermOn®
pivotal clinical trial
LAVAL, Quebec, Canada — August 24, 2006 — BioSyntech Inc. (TSX-V: BSY) announced today that it has received approval from Health Canada, Therapeutic Products Directorate, Medical Devices Bureau, to begin enrolling subjects in its pivotal clinical trial for BST-DermOn®, a medical device designed to repair chronic wounds.
More
-
August 08, 2006
BioSyntech strengthens management team with key appointments.
Company names François Michaud as chief financial officer and Richard Lacombe as vice-president clinical affairs
LAVAL, Québec, Canada — August 8, 2006 — BioSyntech, Inc. (“BioSyntech” or the “Company”) (TSX V: BSY) is pleased to announce the appointments of Mr. François Michaud C.A., C.M.A., as Chief Financial Officer and Mr. Richard Lacombe Ph.D., M.B.A., as Vice-President Clinical Affairs of the Company.
More
-
July 28, 2006
BioSyntech reports major progress in fiscal 2006
Strengthens balance sheet with $28 million financing
Enhances board with additional members
LAVAL, Québec, Canada — July 28, 2006 — BioSyntech, Inc. (“BioSyntech” or “the Company”) (TSX V: BSY) today reported its results for the fiscal year ended March 31, 2006.
More
-
June 13, 2006
BioSyntech strengthens board with new member
LAVAL, Québec, Canada — June 13, 2006 — BioSyntech, Inc. (“BioSyntech” or “the Company”) (TSX V: BSY) today announced the appointment of Dr. Joyce Tsang to its Board of Directors. Dr. Tsang is the representative for ProQuest Investments, which invested in the Company’s recent financing.
More
-
May 25, 2006
BioSyntech appoints new board member
LAVAL, Québec, Canada — May 25, 2006 — BioSyntech, Inc. (“BioSyntech” or “the Company”) (TSX V: BSY) today announced the appointment of Rudy Huber to its board of directors. Mr. Huber is the representative for an institution that invested in the Company’s recent financing.
More
-
May 10, 2006
BioSyntech grants stock options
LAVAL, Quebec, Canada – May 9, 2006 – In accordance with its continuous disclosure obligations, BioSyntech, Inc. (TSX-V: BSY) announces the grant of options to acquire 50,000 common shares of its capital stock at a price of $0.49 per share for a period of five years to a Board Director.
More
-
May 03, 2006
BioSyntech closes its private placement for a total of $21 Million with a $3 Million third and final tranche
LAVAL, Quebec, Canada – May 3rd, 2006 – BioSyntech, Inc. (“BioSyntech” or the “Company”) (TSX V: BSY) announced today the closing of the third tranche of its previously-announced financing. This final tranche involved the issuance of 7,125,000 Units at $0.42 per Unit for a total of $2,996,700. This brings the total financing to $21 million for the issuance of 50,000,000 Units. Each Unit consisted of one common share and half a warrant. Each full warrant entitles the holder to purchase one share at $0.65 prior to March 31, 2009.
More
-
April 18, 2006
BioSyntech closes $8 Million second tranche of its private placement and increases total offering to $21,7 Million
LAVAL, Quebec, Canada – April 17, 2006 – BioSyntech, Inc. (“BioSyntech” or the “Company”) (TSX V: BSY) announced today that it has increased the size of its previously announced private placement to $21,700,000, representing an aggregate of 51,666,666 units, at a price of $0.42 per unit, to accommodate the subscription of two strategic investors.
More
-
March 31, 2006
BIOSYNTECH, INC. ANNOUNCES FIRST CLOSING OF ITS PRIVATE PLACEMENT FOR AN AMOUNT OF $10 MILLION
LAVAL, Quebec, Canada – March 31, 2006 – BioSyntech, Inc. (“BioSyntech” or the “Company”) (TSX V: BSY) announced today a first closing of its private placement involving the issuance of 23,810,000 units at a price of $0.42 per unit for gross proceeds of $10,000,200. Each unit consists of one common share of the Company and one half of one warrant. Each warrant entitles the holder to purchase, for a period of three years, one common share at a price of $0.65 per share.
More
-
March 20, 2006
BioSyntech Inc. announces new closing date for its private placement, continuation under the Canada Business Corporations Act and appointment of new chairman
LAVAL, Quebec, Canada – March 20, 2006 – BioSyntech Inc. (“BioSyntech” or the “Company”) (TSX V: BSY) announced today the appointment of Joseph Benarrosh as Chairman of its board of directors, following the resignation of Amine Selmani, who remains as a board member. Mr. Benarrosh has been a board member of the Company since 2004.
More
-
February 28, 2006
BioSyntech Inc. announces proposed private placement
LAVAL, Quebec, Canada – February 28, 2006 – BioSyntech Inc. (“BioSyntech” or the “Company”) (TSX V: BSY) announced today that it has retained the services of Desjardins Securities Inc. as lead agent and Dundee Securities Corporation (together, the “Agents”) for a private placement of 23,810,000 units of the Company at a price of $0.42 per unit, for gross proceeds of $10,000,200.
More
-
February 24, 2006
BioSyntech reports its third quarter results
LAVAL, Québec, Canada — February 24, 2006 — BioSyntech, Inc. (“BioSyntech” or “the Company”) (TSX V: BSY) today reported its results for its third quarter and nine-month period ended December 31, 2005.
Highlights and subsequent events:
More
-
February 16, 2006
BioSyntech announces extension of BDC loan
LAVAL, Quebec, Canada — February 16, 2006 — BioSyntech, Inc. (“BioSyntech” or the “Company”) (TSX-V: BSY) today announced that it has negotiated the extension until February 15, 2009 of the $2,500,000 loan obtained in 2002 from the Business Development Bank of Canada (the “BDC”), on the same terms and conditions. All outstanding interest due on the initial loan, which had been capitalized since disbursement, was paid.
More
-
February 09, 2006
BioSyntech closes transaction with Kuhnil Pharma Co. LTD
LAVAL, Quebec, Canada — February 9, 2006 — BioSyntech, Inc. (“BioSyntech” or “the Company”) (TSX-V: BSY) today announced the closing of the transaction with Kuhnil Pharma Co. Ltd (“Kuhnil”), one of Korea's leading pharmaceutical companies, pursuant to which Kuhnil purchased 1,500,000 common shares of the Company at a price of $0.80 per share, for total proceeds of $1.2 million.
More
-
January 09, 2006
BioSyntech's BST-CarGel subject of prestigious publication
LAVA |